Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 February 2021Next earnings report:
28 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:52:26 GMTDividend
Analysts recommendations
Institutional Ownership
SABS Latest News
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024.
SAB Biotherapeutics, Inc. (SABS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
SAB Biotherapeutics (NASDAQ:SABS) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapeutic SAB-176 for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains, causing the company's shares to shoot up more than 80%. A Fast Track designation allows drugmakers to expedite the development and review of medicines that target critical illnesses and address unmet medical needs.
What type of business is SAB Biotherapeutics?
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
What sector is SAB Biotherapeutics in?
SAB Biotherapeutics is in the Healthcare sector
What industry is SAB Biotherapeutics in?
SAB Biotherapeutics is in the Biotechnology industry
What country is SAB Biotherapeutics from?
SAB Biotherapeutics is headquartered in United States
When did SAB Biotherapeutics go public?
SAB Biotherapeutics initial public offering (IPO) was on 09 February 2021
What is SAB Biotherapeutics website?
https://www.sabbiotherapeutics.com
Is SAB Biotherapeutics in the S&P 500?
No, SAB Biotherapeutics is not included in the S&P 500 index
Is SAB Biotherapeutics in the NASDAQ 100?
No, SAB Biotherapeutics is not included in the NASDAQ 100 index
Is SAB Biotherapeutics in the Dow Jones?
No, SAB Biotherapeutics is not included in the Dow Jones index
When was SAB Biotherapeutics the previous earnings report?
No data
When does SAB Biotherapeutics earnings report?
The next expected earnings date for SAB Biotherapeutics is 28 March 2025